Stockreport

AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease [Yahoo! Finance]

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson's disease, was well tolerated with no attributed serious adverse event [Read more]